{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.05","upperLimit":"8.54","value":"3.55"},{"groupId":"OG001","lowerLimit":"1.81","upperLimit":"13.14","value":"3.55"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"description":"PFS was defined as the time from the date of first treatment to the date of the first radiographic disease progression or death due to any cause, whichever occurred first.","dispersionType":"95% Confidence Interval","groups":[{"description":"Duvelisib PO BID at a starting dose of 25 mg, with potential escalation on a per-participant basis to 50 mg and then 75 mg, based on the participant's response to and tolerance of therapy, in 28-day cycles.","id":"OG000","title":"Dose Optimization Phase: Cohort 1"},{"description":"Duvelisib 75 mg PO BID, administered in 28-day cycles.","id":"OG001","title":"Dose Optimization Phase: Cohort 2"}],"paramType":"MEDIAN","populationDescription":"Dose Optimization Efficacy Set: All participants who received at least one dose of study drug, completed at least one cycle of treatment, and had at least one scan to assess disease response after completion of one cycle of treatment. Here, 'Overall Number of Participants Analyzed' signifies those participants who were evaluable for this outcome measure. As pre-specified, efficacy analysis using investigator assessment reported for the Dose Optimization Phase only.","reportingStatus":"POSTED","timeFrame":"Up to 70 months","title":"Progression-free Survival (PFS) as Assessed by the Investigator Using the Lugano Criteria","type":"SECONDARY","unitOfMeasure":"month"}